Market Snapshot
S&P Futures
4,132.75
Dow Futures
32,794
Nasdaq Futures
13,103.75
Aprea Therapeutics, Inc. (APRE) stock declined over -1.08% intraday to trade at $0.9793 a share on NASDAQ. The stock opened with a gain of 2.01% at $1 and touched an intraday high of $1.16, falling -1.08% against the last close of $0.99. The stock went to a low of $0.971 during the session.
Prev. Close
Market Cap
Day Low
Open
Number of Shares
Day High
P/E ratio
EPS (TTM)
Cash Flow per Share
Free Float in %
Book Value
Volume
Date | Open | High | Low | Close | Volume |
---|---|---|---|---|---|
2022-08-08 | $1 | $1.16 | $0.971 | $0.979 | 341,300 |
2022-08-05 | $0.96 | $1 | $0.922 | $0.99 | 78,500 |
2022-08-04 | $0.95 | $0.97 | $0.924 | $0.95 | 111,800 |
2022-08-03 | $0.92 | $0.98 | $0.913 | $0.94 | 71,400 |
2022-08-02 | $0.95 | $0.975 | $0.91 | $0.923 | 126,200 |
2022-08-01 | $0.922 | $0.98 | $0.912 | $0.95 | 98,600 |
2022-07-29 | $1.07 | $1.08 | $0.913 | $0.96 | 483,600 |
2022-07-28 | $1.1 | $1.109 | $1.07 | $1.09 | 114,000 |
2022-07-27 | $1.1 | $1.11 | $1.08 | $1.11 | 92,300 |
2022-07-26 | $1.11 | $1.128 | $1.07 | $1.08 | 170,500 |
Employees-
Beta-
Sales or Revenue0
5Y Sales Change-
Fiscal Year Ends2021-12-30
SectorHealth Care
IndustryBiotechnology
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia, as well as for relapsed/refractory TP53 mutant chronic lymphoid leukemia; and gastric, bladder, and non-small cell lung cancers. It also develops APR-548, a p53 reactivator that is on Phase I dose-escalation clinical trial for oral administration in MDS patients. The company was founded in 2006 and is headquartered in Boston, Massachusetts.
Aprea Therapeutics, Inc. (NASDAQ: APRE) stock price is $0.9793 as of the last check on Monday, August 8. During the trading session, APRE stock reached the peak price of $1.16 while $0.971 was the lowest point it dropped to.
The NASDAQ listed APRE is part of Biotechnology industry that operates in the broader Health Care sector. Aprea Therapeutics, Inc. , a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein.
Mr. Christian S. Schade
Pres, CEO & Chairman
Mr. Scott M. Coiante
Sr. VP, Company Sec. & CFO
Dr. Eyal C. Attar M.D.
Sr. VP & Chief Medical Officer
Dr. Lars B. Abrahmsen
Sr. VP & Chief Scientific Officer
APRE stock traded closed the last session at $0.979, which is -$0.010700000000000043 or -1.080808080808085% lower than its previous close of $0.99. APRE's current trading price is 57.95% lower than its 52-week high of $5.67 where as its distance from 52-week low of 0.62% is -82.73%.
Number of APRE employees currently stands at -. APRE operates from 535 Boylston Street, Boston, MA 02116, United States.
Official Webiste of $APRE is: https://www.aprea.com
APRE could be contacted at APRE operates from 535 Boylston Street, Boston, MA 02116, United States, or at phone #617 463 9385 and can also be accessed through its website.
APRE stock volume for the day was 341,300 shares while in the previous session number of APRE shares traded was 341,300 . The average number of APRE shares traded daily for last 3 months was 916.65 Thousands.
The percentage change in APRE stock occurred in the recent session was -1.080808080808085% while the dollar amount for the price change in APRE stock was -$0.010700000000000043.
In the recent session, the day high for APRE stock was $1.16 while the low for APRE stock touched on the day was $0.971.
The market value of APRE currently stands at 21.96 Million with its latest stock price at $0.9793 and 21.9 Million of its shares outstanding.